Ipamorelin Reference
Educational, not medical advice reference for Ipamorelin: GH Release, Sleep; regulatory status, evidence posture, source review, and schedule no…
Plain English
- What it is
- Ipamorelin is a lab-made peptide that signals the body to put out a short pulse of its own growth hormone. It is not an FDA-approved medicine and has no approved drug label. It is handled as a research chemical, not a treatment, and it is not hormone replacement.
- What people use it for
- In the peptide community it is seen as the 'cleaner' growth-hormone-pulse option, picked for recovery, sleep, and lean-muscle goals because people believe it skips the extra hunger and stress-hormone bump linked to older peptides in its class. It is often paired with another peptide called CJC-1295. The effects people report tend to be described as subtle and gradual rather than dramatic.
- What the science shows
- Early studies in healthy adults confirmed that it triggers a growth-hormone release, and older animal research described it as the first of its kind to do this without raising the stress hormone cortisol. But the human studies are small and short-term, and there is little data on long-term results or safety in real-world use.
- The catch
- Because it is not an approved drug, there is no standard quality check on what is actually in a vial, so the amount and purity can vary and measuring mistakes are easier to make. An FDA advisory committee reviewed ipamorelin for pharmacy compounding rather than approving it as a medicine. Much of what people share about results is personal experience, not proof from large human trials.
Reference summary
Early human PK/PD work in healthy volunteers confirmed GH release across dose levels, while older preclinical pharmacology emphasized relative selectivity versus older GHRPs. Long-term clinical outcome data remain limited.
Regulatory and posture
- Categories
- GH Release, Sleep
- Aliases
- Ipamorelin acetate, NNC 26-0161
- Evidence posture
- human - Small short-term endocrine studies only. Long-term outcome data are limited.
- Regulatory status
- No FDA-approved ipamorelin drug label. In September 2024 FDA's Pharmacy Compounding Advisory Committee listed ipamorelin acetate and ipamorelin (free base) among bulk drug substances being considered for inclusion on the Section 503A Bulks List, so its compounding status is under active FDA review and it remains not FDA-approved.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- FDA Federal Register notice (Sept 18, 2024): Pharmacy Compounding Advisory Committee considered ibutamoren mesylate, ipamorelin, and kisspeptin-10 for the 503A Bulks List
- PubMed: ipamorelin human PK/PD trial
- PubMed: ipamorelin preclinical pharmacology
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
For research and educational purposes only. Not medical advice.